Catalyst Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Catalyst Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CPRX

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. 

CEO
Richard John Daly
CEORichard John Daly
Employees
181
Employees181
Headquarters
Coral Gables, Florida
HeadquartersCoral Gables, Florida
Founded
2002
Founded2002
Employees
181
Employees181

CPRX Key Statistics

Market cap
2.90B
Market cap2.90B
Price-Earnings ratio
14.27
Price-Earnings ratio14.27
Dividend yield
Dividend yield
Average volume
1.31M
Average volume1.31M
High today
$24.60
High today$24.60
Low today
$23.41
Low today$23.41
Open price
$24.34
Open price$24.34
Volume
1.07M
Volume1.07M
52 Week high
$26.58
52 Week high$26.58
52 Week low
$19.05
52 Week low$19.05

Stock Snapshot

Catalyst Pharmaceuticals(CPRX) stock is priced at $23.58, giving the company a market capitalization of 2.9B. It carries a P/E multiple of 14.27.

On 2026-01-24, Catalyst Pharmaceuticals(CPRX) stock traded between a low of $23.41 and a high of $24.60. Shares are currently priced at $23.58, which is +0.7% above the low and -4.1% below the high.

Catalyst Pharmaceuticals(CPRX) shares are trading with a volume of 1.07M, against a daily average of 1.31M.

In the last year, Catalyst Pharmaceuticals(CPRX) shares hit a 52-week high of $26.58 and a 52-week low of $19.05.

In the last year, Catalyst Pharmaceuticals(CPRX) shares hit a 52-week high of $26.58 and a 52-week low of $19.05.

CPRX News

Simply Wall St 3d
Assessing Catalyst Pharmaceuticals Valuation After Fresh Rare Disease Momentum And Earnings Outperformance

Advertisement Why recent attention on Catalyst Pharmaceuticals matters Recent commentary around Catalyst Pharmaceuticals (CPRX) has focused on its rare diseas...

Assessing Catalyst Pharmaceuticals Valuation After Fresh Rare Disease Momentum And Earnings Outperformance
TipRanks 5d
Catalyst Pharmaceuticals: Rare-Disease Buy-and-Build Strategy, Strong Launches, and Capital Flexibility Underpin Buy Rating

Analyst Pavan Patel of Bank of America Securities maintained a Buy rating on Catalyst Pharma, retaining the price target of $35.00. Claim 50% Off TipRanks Premi...

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CPRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.